Patents Assigned to Nippon Zenyaku Kogyo Co., Ltd.
  • Patent number: 10280223
    Abstract: The object of the present invention is to provide an anti-canine PD-1 antibody or an anti-canine PD-L1 antibody, an agent for inhibiting binding between a canine PD-1 and a canine PD-L1 containing such an antibody, a method for inhibiting binding between a canine PD-1 and a canine PD-L1 comprising using such an antibody, and a gene encoding such an antibody. An anti-canine PD-1 antibody that specifically binds to a canine PD-1 consisting of the amino acid sequence set forth in SEQ ID NO: 1 and an anti-canine PD-L1 antibody that specifically binds to a canine PD-L1 consisting of the amino acid sequence set forth in SEQ ID NO: 6 are produced. An agent for inhibiting binding between a canine PD-1 and a canine PD-L1 containing such an antibody is also produced.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: May 7, 2019
    Assignee: NIPPON ZENYAKU KOGYO CO., LTD.
    Inventors: Takuya Mizuno, Kazuha Shosu
  • Publication number: 20180319879
    Abstract: Provided are an anti-canine TARC antibody for use in the treatment and diagnosis of canine atopic dermatitis, and a method for treating or diagnosing canine atopic dermatitis using the same. An anti-canine TARC monoclonal antibody binding to canine TARC, comprising a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 2 and a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 4, or a functional fragment thereof binding to canine TARC.
    Type: Application
    Filed: October 13, 2016
    Publication date: November 8, 2018
    Applicant: NIPPON ZENYAKU KOGYO CO., LTD.
    Inventors: Toshihiro TSUKUI, Miyuki KAGEYAMA, Masahiro KATO, Rieko SUZUKI
  • Patent number: 9850317
    Abstract: Problem to be Solved: The present invention is intended to provide a polynucleotide encoding the light-chain variable region and the heavy-chain variable region of an anti-dog IgE antibody; and an anti-dog IgE antibody containing these variable regions. Solution: The present invention is DNA encoding a heavy-chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 2 or 6 and DNA encoding a light-chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 4 or 8, and an anti-dog IgE monoclonal antibody which binds to dog IgE, containing these variable regions or a functional fragment thereof which binds to dog IgE.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: December 26, 2017
    Assignees: KAZUSA DNA RESEARCH INSTITUTE, ANIMAL ALLERGY CLINICAL LABORATORIES INC., NIPPON ZENYAKU KOGYO CO., LTD.
    Inventors: Osamu Ohara, Takahiro Nagase, Yoshihiro Yamaguchi, Reiko Ohara, Kenichi Masuda, Toshihiro Tsukui
  • Patent number: 9732107
    Abstract: This invention provides a method of preparing a ?-hematin crystal comprising a step of heating, the ?-hematin crystal obtained by such method, and a vaccine adjuvant composition containing the ?-hematin crystal. The ?-hematin crystal has a needle-like morphology, it has an average particle size of 0.6 to 1.2 ?m, and it exhibits main peaks characteristics for angles of diffraction (2?) of 7.4°, 12.2°, 21.6°, and 24.1° in an X-ray diffraction pattern obtained by powder X-ray diffractometry with Cu—K? rays (with each peak including a plus-minus 0.2° diffraction angle).
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: August 15, 2017
    Assignees: Osaka University, Nippon Zenyaku Kogyo Co., Ltd.
    Inventors: Shizuo Akira, Ken Ishii, Cevayir Coban, Yoshikatsu Igari, Yasumasa Kano, Akina Otsuki
  • Publication number: 20170158764
    Abstract: The object of the present invention is to provide an anti-canine PD-1 antibody or an anti-canine PD-L1 antibody, an agent for inhibiting binding between a canine PD-1 and a canine PD-L1 containing such an antibody, a method for inhibiting binding between a canine PD-1 and a canine PD-L1 comprising using such an antibody, and a gene encoding such an antibody. An anti-canine PD-1 antibody that specifically binds to a canine PD-1 consisting of the amino acid sequence set forth in SEQ ID NO: 1 and an anti-canine PD-L1 antibody that specifically binds to a canine PD-L1 consisting of the amino acid sequence set forth in SEQ ID NO: 6 are produced. An agent for inhibiting binding between a canine PD-1 and a canine PD-L1 containing such an antibody is also produced.
    Type: Application
    Filed: July 8, 2015
    Publication date: June 8, 2017
    Applicant: NIPPON ZENYAKU KOGYO CO., LTD.
    Inventors: Takuya MIZUNO, Kazuha SHOSU
  • Patent number: 9657071
    Abstract: It is intended to provide an IgE peptide vaccine that can be used in the prevention or treatment of allergic diseases in animals other than mice, such as humans or dogs. The present invention provides a peptide consisting of (i) the amino acid sequence represented by SEQ ID NO: 28, or (ii) an amino acid sequence consisting of at least 10 consecutive amino acids in the amino acid sequence represented by SEQ ID NO: 28, wherein the peptide, when administered to an animal, is capable of specifically binding to a CH3 region in an IgE antibody of the animal and thereby blocking the binding of the IgE antibody to an IgE receptor.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: May 23, 2017
    Assignee: NIPPON ZENYAKU KOGYO CO., LTD.
    Inventor: Toshihiro Tsukui
  • Publication number: 20160272728
    Abstract: Problem to be Solved: The present invention is intended to provide a polynucleotide encoding the light-chain variable region and the heavy-chain variable region of an anti-dog IgE antibody; and an anti-dog IgE antibody containing these variable regions. Solution: The present invention is DNA encoding a heavy-chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 2 or 6 and DNA encoding a light-chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 4 or 8, and an anti-dog IgE monoclonal antibody which binds to dog IgE, containing these variable regions or a functional fragment thereof which binds to dog IgE.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 22, 2016
    Applicants: KAZUSA DNA RESEARCH INSTITUTE, NIPPON ZENYAKU KOGYO CO., LTD., ANIMAL ALLERGY CLINICAL LABORATORIES INC.
    Inventors: Osamu OHARA, Takahiro NAGASE, Yoshihiro YAMAGUCHI, Reiko OHARA, Kenichi MASUDA, Toshihiro TSUKUI
  • Publication number: 20160122378
    Abstract: This invention provides a method of preparing a ?-hematin crystal comprising a step of heating, the ?-hematin crystal obtained by such method, and a vaccine adjuvant composition containing the ?-hematin crystal. The ?-hematin crystal has a needle-like morphology, it has an average particle size of 0.6 to 1.2 ?m, and it exhibits main peaks characteristics for angles of diffraction (2?) of 7.4°, 12.2°, 21.6°, and 24.1° in an X-ray diffraction pattern obtained by powder X-ray diffractometry with Cu—K? rays (with each peak including a plus-minus 0.2° diffraction angle).
    Type: Application
    Filed: June 4, 2014
    Publication date: May 5, 2016
    Applicants: OSAKA UNIVERSITY, NIPPON ZENYAKU KOGYO CO., LTD.
    Inventors: Shizuo AKIRA, Ken ISHII, Cevayir COBAN, Yoshikatsu IGARI, Yasumasa KANO, Akina OTSUKI
  • Patent number: 9056094
    Abstract: The present invention provides a vaccine adjuvant composition which is used in combination with an allergen vaccine, infection vaccine or tumor vaccine. The present invention specifically provides a vaccine adjuvant composition comprising hemozoin or ?-hematin and being used in combination with an allergen vaccine, infection vaccine or tumor vaccine, and a vaccine composition comprising the vaccine adjuvant composition and an allergen vaccine, infection vaccine or tumor vaccine.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: June 16, 2015
    Assignees: NIPPON ZENYAKU KOGYO CO., LTD., OSAKA UNIVERSITY
    Inventors: Toshihiro Tsukui, Ken Ishii, Shizuo Akira, Cevayir Coban
  • Patent number: 8962705
    Abstract: A method for removing cauxin in cat urine and a material for removing cauxin are provided. The material for removing cauxin in cat urine comprises a polymer substrate on which surface a trifluoroketone derivative is immobilized via dithiol.
    Type: Grant
    Filed: February 17, 2011
    Date of Patent: February 24, 2015
    Assignees: National University Corporation Chiba University, Incorporated National University Iwate University, Nippon Zenyaku Kogyo Co., Ltd.
    Inventors: Shinya Matsuno, Kyoichi Saito, Tetsuro Yamashita, Ayako Ito, Yasuyuki Suzuta
  • Publication number: 20140080997
    Abstract: A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following recombinant protein (a) or (b) is provided: (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 2 or 35; or (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 or 35 by deletion, substitution, or addition of one or several amino acids and having mite allergen activity.
    Type: Application
    Filed: October 14, 2013
    Publication date: March 20, 2014
    Applicant: NIPPON ZENYAKU KOGYO CO., LTD.
    Inventors: Toshihiro TSUKUI, Hajime TSUJIMOTO, Shigehiro IWABUCHI
  • Patent number: 8647630
    Abstract: A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following recombinant protein (a) or (b) is provided: (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 2 or 35; or (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 or 35 by deletion, substitution, or addition of one or several amino acids and having mite allergen activity.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: February 11, 2014
    Assignee: Nippon Zenyaku Kogyo Co., Ltd.
    Inventors: Toshihiro Tsukui, Hajime Tsujimoto, Shigehiro Iwabuchi
  • Patent number: 8460926
    Abstract: To provide an aqueous solution for cell preservation which is free of a natural animal-derived component such as a basal medium or serum. An aqueous preservation solution showing a high cell survival rate was obtained by removing a natural animal-derived component such as a basal medium or serum and controlling other components and their concentrations.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: June 11, 2013
    Assignee: Nippon Zenyaku Kogyo Co., Ltd
    Inventors: Naoto Yamashiro, Kohichi Saze, Osamu Ohneda, Masumi Nagano
  • Patent number: 8415163
    Abstract: Disclosed is a method of diagnosing renal dysfunction in a cat by removing cauxin from cat urine and detecting a protein in the cat urine sample from which cauxin has been removed. Cauxin is removed from cat urine by bringing the cat urine into contact with a lectin or with an anti-cauxin antibody that specifically binds to cauxin. Cauxin may be removed using a column filled with a carrier that is bound to the lectin or to the anti-cauxin antibody. The lectin may be Lens culinaris lectin. Detection of the cat urinary protein from which cauxin has been removed is performed with a urine test strip.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: April 9, 2013
    Assignees: Incorporated National University Iwate University, Nippon Zenyaku Kogyo Co., Ltd.
    Inventors: Tetsuro Yamashita, Yasuyuki Suzuta
  • Publication number: 20130034731
    Abstract: The present invention is directed to providing a method for preparing a vaccine adjuvant composition containing ?-hematin and a vaccine adjuvant composition obtained by the preparation method. The present invention is directed to a vaccine adjuvant composition containing a ?-hematin crystal having an average particle size of 20 to 500 nm.
    Type: Application
    Filed: December 17, 2010
    Publication date: February 7, 2013
    Applicants: NIPPON ZENYAKU KOGYO CO., LTD., OSAKA UNIVERSITY
    Inventors: Shizuo Akira, Ken Ishii, Cevayir Coban, Toshihiro Tsukui, Yoshikatsu Igari, Keiichi Ohata
  • Publication number: 20120309110
    Abstract: A method for diagnosing a kidney disease in a cat by detecting a cat urinary protein without being affected by cauxin, and a diagnostic agent therefor are provided. A method of detecting a urinary protein derived from renal dysfunction in a cat according to claim 1, wherein cauxin is removed from cat urine by bringing the cat urine into contact with a lectin or an anti-cauxin antibody that specifically binds to cauxin.
    Type: Application
    Filed: August 16, 2012
    Publication date: December 6, 2012
    Applicants: NIPPON ZENYAKU KOGYO CO., LTD., INCORPORATED NATIONAL UNIVERSITY IWATE UNIVERSITY
    Inventors: Tetsuro YAMASHITA, Yasuyuki Suzuta
  • Publication number: 20120289679
    Abstract: A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following recombinant protein (a) or (b) is provided: (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 2 or 35; or (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 or 35 by deletion, substitution, or addition of one or several amino acids and having mite allergen activity.
    Type: Application
    Filed: September 12, 2011
    Publication date: November 15, 2012
    Applicant: NIPPON ZENYAKU KOGYO CO., LTD.
    Inventors: Toshihiro TSUKUI, Hajime TSUJIMOTO, Shigehiro IWABUCHI
  • Patent number: 8268639
    Abstract: A method for diagnosing a kidney disease in a cat by detecting a cat urinary protein without being affected by cauxin, and a diagnostic agent therefor are provided. A method of detecting a urinary protein derived from renal dysfunction in a cat according to claim 1, wherein cauxin is removed from cat urine by bringing the cat urine into contact with a lectin or an anti-cauxin antibody that specifically binds to cauxin.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: September 18, 2012
    Assignees: Incorporated National University Iwate University, Nippon Zenyaku Kogyo Co., Ltd.
    Inventors: Tetsuro Yamashita, Yasuyuki Suzuta
  • Patent number: 8075898
    Abstract: A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following recombinant protein (a) or (b) is provided: (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 2 or 35; or (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 or 35 by deletion, substitution, or addition of one or several amino acids and having mite allergen activity.
    Type: Grant
    Filed: April 7, 2005
    Date of Patent: December 13, 2011
    Assignee: Nippon Zenyaku Kogyo Co., Ltd.
    Inventors: Toshihiro Tsukui, Hajime Tsujimoto, Shigehiro Iwabuchi
  • Publication number: 20110091490
    Abstract: This invention provides vaccines against canine distemper virus infections, canine adenovirus type 2 infections, and canine parvovirus infections that can be orally administered. The invention also provides the attenuated canine distemper virus strain obtained by adapting the canine distemper virus 95-54 strains in cultured cells to attenuate the same, the attenuated canine adenovirus type 2 strain obtained by adapting the canine adenovirus type 2 F1 strain in cultured cells to attenuate the same, and an attenuated canine parvovirus strain obtained by adapting the canine parvovirus F3 strain in cultured cells to attenuate the same.
    Type: Application
    Filed: September 13, 2007
    Publication date: April 21, 2011
    Applicant: NIPPON ZENYAKU KOGYO CO., LTD.
    Inventors: Masayuki Okazaki, Takahiro Yoshimura, Toshihiro Tsukui, Shigehiro Iwabuchi